Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Gynecology

Free Subscription Articles published in Lancet Retrieve available abstracts of 133 articles: HTML format

Single Articles

April 2024
1. STRAND TA, McCann A, Kvestad I, Chandyo RK, et al
   Vitamin B12 deficiency in pregnant women - Authors' reply.
   Lancet. 2024;403:1450.
   PubMed    
   
   
   
2. SEN S
   Vitamin B12 deficiency in pregnant women.
   Lancet. 2024;403:1449-1450.
   PubMed    
   
   
   March 2024
3. JOHANSSON K, Bodnar LM, Stephansson O, Abrams B, et al
   Safety of low weight gain or weight loss in pregnancies with class 1, 2, and 3 obesity: a population-based cohort study.
   Lancet. 2024 Mar 28:S0140-6736(24)00255-1. doi: 10.1016/S0140-6736(24)00255.
   PubMed     Abstract available
   
   
   
4. GAILLARD R
   Optimising gestational weight gain among pregnant women with obesity.
   Lancet. 2024 Mar 28:S0140-6736(24)00470-7. doi: 10.1016/S0140-6736(24)00470.
   PubMed    
   
   
   
5. LORUSSO D, Xiang Y, Hasegawa K, Scambia G, et al
   Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
   Lancet. 2024 Mar 20:S0140-6736(24)00317-9. doi: 10.1016/S0140-6736(24)00317.
   PubMed     Abstract available
   
   
   
6. TEWARI KS, Monk BJ
   Immunotherapy plus chemoradiotherapy in cervical cancer management.
   Lancet. 2024 Mar 20:S0140-6736(24)00468-9. doi: 10.1016/S0140-6736(24)00468.
   PubMed    
   
   
   
7. HEISLER M, Mitchell N, Arey W, Erenberg M, et al
   US abortion bans should not pre-empt the duty to provide life-saving abortion care to pregnant patients in medical emergencies.
   Lancet. 2024 Mar 19:S0140-6736(24)00551-8. doi: 10.1016/S0140-6736(24)00551.
   PubMed    
   
   
   
8. DADOUN S, Demmler-Harrison GJ, Ketwaroo P, Castro EC, et al
   Congenital toxoplasmosis of the brain caused by infection in late pregnancy.
   Lancet. 2024;403:1081-1082.
   PubMed    
   
   
   
9. MISHRA GD, Davies MC, Hillman S, Chung HF, et al
   Optimising health after early menopause.
   Lancet. 2024;403:958-968.
   PubMed     Abstract available
   
   
   
10. HICKEY M, Basu P, Sassarini J, Stegmann ME, et al
    Managing menopause after cancer.
    Lancet. 2024;403:984-996.
    PubMed     Abstract available
    
    
    
11. BROWN L, Hunter MS, Chen R, Crandall CJ, et al
    Promoting good mental health over the menopause transition.
    Lancet. 2024;403:969-983.
    PubMed     Abstract available
    
    
    
12. HICKEY M, LaCroix AZ, Doust J, Mishra GD, et al
    An empowerment model for managing menopause.
    Lancet. 2024;403:947-957.
    PubMed     Abstract available
    
    
    
13. HAWKES P, Scott J, Hickey M
    500 Strong: celebrating older women's bodies in menopause and beyond.
    Lancet. 2024;403:894-903.
    PubMed    
    
    
    
14. SAMARASEKERA U
    Martha Hickey: responding to the complexity of menopause.
    Lancet. 2024;403:893.
    PubMed    
    
    
    
15. THE LANCET
    Time for a balanced conversation about menopause.
    Lancet. 2024;403:877.
    PubMed    
    
    
    
16. NIELSEN OH, Gubatan JM, Kolho KL, Streett SE, et al
    Updates on the management of inflammatory bowel disease from periconception to pregnancy and lactation.
    Lancet. 2024 Mar 5:S0140-6736(24)00052-7. doi: 10.1016/S0140-6736(24)00052.
    PubMed     Abstract available
    
    
    
17. ZAROCOSTAS J
    Renewed calls to scale-up cervical cancer screening.
    Lancet. 2024;403:797.
    PubMed    
    
    
    February 2024
18. PETERS RPH, Klausner JD, Mazzola L, Mdingi MM, et al
    Novel lateral flow assay for point-of-care detection of Neisseria gonorrhoeae infection in syndromic management settings: a cross-sectional performance evaluation.
    Lancet. 2024;403:657-664.
    PubMed     Abstract available
    
    
    
19. THORNTON J
    Reducing patchiness in abortion care in the UK.
    Lancet. 2024 Feb 15:S0140-6736(24)00312-X. doi: 10.1016/S0140-6736(24)00312.
    PubMed    
    
    
    
20. HURRELL A, Webster L, Sparkes J, Battersby C, et al
    Repeat placental growth factor-based testing in women with suspected preterm pre-eclampsia (PARROT-2): a multicentre, parallel-group, superiority, randomised controlled trial.
    Lancet. 2024 Feb 8:S0140-6736(23)02357-7. doi: 10.1016/S0140-6736(23)02357.
    PubMed     Abstract available
    
    
    
21. CERDEIRA AS, Karumanchi SA
    Serial placental growth factor-based testing in pre-eclampsia.
    Lancet. 2024 Feb 8:S0140-6736(23)02578-3. doi: 10.1016/S0140-6736(23)02578.
    PubMed    
    
    
    
22. LUCAS N, Rex S, Devroe S
    Treatment modalities for placenta accreta spectrum.
    Lancet. 2024;403:437.
    PubMed    
    
    
    
23. MORLEY LC, Sparey C, Wijeratne D, Turner K, et al
    Treatment modalities for placenta accreta spectrum - Authors' reply.
    Lancet. 2024;403:437-438.
    PubMed    
    
    
    January 2024
24. KAMYA MR, Kakuru A, Dorsey G
    Dihydroartemisinin-piperaquine for prevention of malaria in pregnant women living with HIV.
    Lancet. 2024 Jan 12:S0140-6736(24)00048-5. doi: 10.1016/S0140-6736(24)00048.
    PubMed    
    
    
    
25. BARSOSIO HC, Madanitsa M, Ondieki ED, Dodd J, et al
    Chemoprevention for malaria with monthly intermittent preventive treatment with dihydroartemisinin-piperaquine in pregnant women living with HIV on daily co-trimoxazole in Kenya and Malawi: a randomised, double-blind, placebo-controlled trial.
    Lancet. 2024 Jan 12:S0140-6736(23)02631-4. doi: 10.1016/S0140-6736(23)02631.
    PubMed     Abstract available
    
    
    
26. RIAL-CRESTELO M, Lubusky M, Parra-Cordero M, Krofta L, et al
    Term planned delivery based on fetal growth assessment with or without the cerebroplacental ratio in low-risk pregnancies (RATIO37): an international, multicentre, open-label, randomised controlled trial.
    Lancet. 2024 Jan 11:S0140-6736(23)02228-6. doi: 10.1016/S0140-6736(23)02228.
    PubMed     Abstract available
    
    
    
27. ELNAKIB S, Fair M, Mayrhofer E, Afifi M, et al
    Pregnant women in Gaza require urgent protection.
    Lancet. 2024 Jan 11:S0140-6736(23)02835-0. doi: 10.1016/S0140-6736(23)02835.
    PubMed    
    
    
    December 2023
28. CHAILLET N, Masse B, Grobman WA, Shorten A, et al
    Perinatal morbidity among women with a previous caesarean delivery (PRISMA trial): a cluster-randomised trial.
    Lancet. 2023 Dec 11:S0140-6736(23)01855-X. doi: 10.1016/S0140-6736(23)01855.
    PubMed     Abstract available
    
    
    
29. OAKNIN A, Gladieff L, Martinez-Garcia J, Villacampa G, et al
    Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.
    Lancet. 2023 Dec 1:S0140-6736(23)02405-4. doi: 10.1016/S0140-6736(23)02405.
    PubMed     Abstract available
    
    
    
30. MILESHKIN LR, Manoharan S
    Improving survival from metastatic, recurrent, or persistent cervical cancer.
    Lancet. 2023 Dec 1:S0140-6736(23)02690-9. doi: 10.1016/S0140-6736(23)02690.
    PubMed    
    
    
    November 2023
31. ADEPOJU P
    Nigeria targets almost 8 million girls with HPV vaccine.
    Lancet. 2023;402:1612.
    PubMed    
    
    
    
32. SINGH M, Wambua S, Lee SI, Okoth K, et al
    Autoimmune diseases and adverse pregnancy outcomes: an umbrella review.
    Lancet. 2023;402 Suppl 1:S84.
    PubMed     Abstract available
    
    
    
33. HOBSON G, Dennis N
    Experiences of menopause in the Welsh NHS workplace: a focus group study.
    Lancet. 2023;402 Suppl 1:S51.
    PubMed     Abstract available
    
    
    
34. JONG FC, Kotzur M, Amiri R, Ling J, et al
    Using a participatory approach to encourage uptake of breast, colorectal, and cervical cancer screening for Scottish Muslim women: a pilot qualitative study.
    Lancet. 2023;402 Suppl 1:S12.
    PubMed     Abstract available
    
    
    
35. COWLING A, Nevens L, Contogiorgi N, Bradley N, et al
    Developing and piloting an intervention to reduce colposcopy non-attendance and corresponding inequalities: a mixed-methods study.
    Lancet. 2023;402 Suppl 1:S35.
    PubMed     Abstract available
    
    
    October 2023
36. KOTANI T, Tano S
    Long-term effects of gestational weight gain on mortality.
    Lancet. 2023 Oct 19:S0140-6736(23)01837-8. doi: 10.1016/S0140-6736(23)01837.
    PubMed    
    
    
    
37. HINKLE SN, Mumford SL, Grantz KL, Mendola P, et al
    Gestational weight change in a diverse pregnancy cohort and mortality over 50 years: a prospective observational cohort study.
    Lancet. 2023 Oct 19:S0140-6736(23)01517-9. doi: 10.1016/S0140-6736(23)01517.
    PubMed     Abstract available
    
    
    
38. BHAN N, McDougal L
    Centring agency and norms to meet the health needs of pregnant adolescents.
    Lancet. 2023 Oct 11:S0140-6736(23)02226-2. doi: 10.1016/S0140-6736(23)02226.
    PubMed    
    
    
    
39. SABET F, Prost A, Rahmanian S, Al Qudah H, et al
    The forgotten girls: the state of evidence for health interventions for pregnant adolescents and their newborns in low-income and middle-income countries.
    Lancet. 2023 Oct 11:S0140-6736(23)01682-3. doi: 10.1016/S0140-6736(23)01682.
    PubMed     Abstract available
    
    
    August 2023
40. YAQUB S, Bjork I, Sugulle M, Folseraas T, et al
    Biopsy helpful in diagnosing a liver mass in pregnancy: focal nodular hyperplasia.
    Lancet. 2023;402:e10.
    PubMed    
    
    
    
41. JAFFE S
    Abortion foes threaten PEPFAR.
    Lancet. 2023;402:598.
    PubMed    
    
    
    
42. CAHILL EP
    Adding a COX-2 inhibitor improves efficacy of emergency contraception.
    Lancet. 2023 Aug 16:S0140-6736(23)01612-4. doi: 10.1016/S0140-6736(23)01612.
    PubMed    
    
    
    
43. LI RHW, Lo SST, Gemzell-Danielsson K, Fong CHY, et al
    Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial.
    Lancet. 2023 Aug 16:S0140-6736(23)01240-0. doi: 10.1016/S0140-6736(23)01240.
    PubMed     Abstract available
    
    
    July 2023
44. DASGUPTA N, Ajazi EM, Schwartz TA, Marshall SW, et al
    Misclassification of overdose events in the X:BOT study.
    Lancet. 2023 Jul 19:S0140-6736(23)00113-7. doi: 10.1016/S0140-6736(23)00113.
    PubMed    
    
    
    
45. SABBAH N, Demar M, Sogbo F, Zappa M, et al
    Recurrent vomiting and confusion in pregnancy: hypercalcaemia due to parathyroid adenoma.
    Lancet. 2023;402:62-63.
    PubMed    
    
    
    
46. STRANDELL A, Hellgren M
    Time to stop routine prescription of low-molecular-weight heparin to women with recurrent pregnancy loss and inherited thrombophilia.
    Lancet. 2023;402:6-7.
    PubMed    
    
    
    June 2023
47. CLUVER CA, Walker SP
    Early delivery for pre-eclampsia might save lives in low-income and middle-income settings.
    Lancet. 2023 Jun 29:S0140-6736(23)00824-3. doi: 10.1016/S0140-6736(23)00824.
    PubMed    
    
    
    
48. BEARDMORE-GRAY A, Vousden N, Seed PT, Vwalika B, et al
    Planned delivery or expectant management for late preterm pre-eclampsia in low-income and middle-income countries (CRADLE-4): a multicentre, open-label, randomised controlled trial.
    Lancet. 2023 Jun 29:S0140-6736(23)00688-8. doi: 10.1016/S0140-6736(23)00688.
    PubMed     Abstract available
    
    
    
49. LUCAS DN, Bamber JH, Quasim S
    Perinatal outcomes and the role of obstetric anaesthesia interventions.
    Lancet. 2023;401:2038-2039.
    PubMed    
    
    
    
50. QUENBY S, Booth K, Hiller L, Coomarasamy A, et al
    Heparin for women with recurrent miscarriage and inherited thrombophilia (ALIFE2): an international open-label, randomised controlled trial.
    Lancet. 2023 Jun 1:S0140-6736(23)00693-1. doi: 10.1016/S0140-6736(23)00693.
    PubMed     Abstract available
    
    
    May 2023
51. SHAHEEN-HUSSAIN S, Lombard A, Basile S
    Confronting medical colonialism and obstetric violence in Canada.
    Lancet. 2023;401:1763-1765.
    PubMed    
    
    
    
52. MCCURRY J
    Japan approves abortion pill.
    Lancet. 2023;401:1558.
    PubMed    
    
    
    
53. MOHIDDIN A, Semrau KEA, Simon J, Langlois EV, et al
    The ethical, economic, and developmental imperative to prevent small vulnerable newborns and stillbirths: essential actions to improve the country and global response.
    Lancet. 2023 May 5:S0140-6736(23)00721-3. doi: 10.1016/S0140-6736(23)00721.
    PubMed    
    
    
    April 2023
54. HEISLER M, Cox-Toure T, Kaufman R
    US abortion bans violate patients' right to information and to health.
    Lancet. 2023 Apr 24:S0140-6736(23)00808-5. doi: 10.1016/S0140-6736(23)00808.
    PubMed    
    
    
    
55. JAFFE S
    Drug developers caution against US mifepristone ban.
    Lancet. 2023;401:1325-1326.
    PubMed    
    
    
    
56. SHAND AW, Kidson-Gerber GL
    Anaemia in pregnancy: a major global health problem.
    Lancet. 2023 Apr 20:S0140-6736(23)00396-3. doi: 10.1016/S0140-6736(23)00396.
    PubMed    
    
    
    
57. PASRICHA SR, Mwangi MN, Moya E, Ataide R, et al
    Ferric carboxymaltose versus standard-of-care oral iron to treat second-trimester anaemia in Malawian pregnant women: a randomised controlled trial.
    Lancet. 2023 Apr 20:S0140-6736(23)00278-7. doi: 10.1016/S0140-6736(23)00278.
    PubMed     Abstract available
    
    
    
58. CHANDYO RK, Kvestad I, Ulak M, Ranjitkar S, et al
    The effect of vitamin B12 supplementation during pregnancy on infant growth and development in Nepal: a community-based, double-blind, randomised, placebo-controlled trial.
    Lancet. 2023 Apr 6:S0140-6736(23)00346-X. doi: 10.1016/S0140-6736(23)00346.
    PubMed     Abstract available
    
    
    March 2023
59. BERGH C, Lundin K
    No benefit to pregnancy or livebirth by time-lapse-based embryo selection in IVF.
    Lancet. 2023 Mar 30:S0140-6736(23)00219-2. doi: 10.1016/S0140-6736(23)00219.
    PubMed    
    
    
    
60. LEDERMAN S, Ottery FD, Cano A, Santoro N, et al
    Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.
    Lancet. 2023 Mar 13:S0140-6736(23)00085-5. doi: 10.1016/S0140-6736(23)00085.
    PubMed     Abstract available
    
    
    
61. PRAGUE JK
    Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms.
    Lancet. 2023 Mar 13:S0140-6736(23)00353-7. doi: 10.1016/S0140-6736(23)00353.
    PubMed    
    
    
    
62. MORLEY LC, Sparey C, Wijeratne D, Turner K, et al
    A planned caesarean hysterectomy for placenta accreta spectrum at 35 weeks of gestation: antenatal identification and a multidisciplinary approach to manage an increasing condition.
    Lancet. 2023;401:856-857.
    PubMed    
    
    
    
63. CLUVER C, de Groot C, Mol BW, Murphy KE, et al
    The need for appropriate language in the debate on medicalisation of pregnancy.
    Lancet. 2023;401:818-819.
    PubMed    
    
    
    
64. KAKURU A, Jagannathan P
    Can we reduce malaria in pregnancy and improve birth outcomes?
    Lancet. 2023 Mar 10:S0140-6736(23)00101-0. doi: 10.1016/S0140-6736(23)00101.
    PubMed    
    
    
    
65. MADANITSA M, Barsosio HC, Minja DTR, Mtove G, et al
    Effect of monthly intermittent preventive treatment with dihydroartemisinin-piperaquine with and without azithromycin versus monthly sulfadoxine-pyrimethamine on adverse pregnancy outcomes in Africa: a double-blind randomised, partly placebo-controlle
    Lancet. 2023 Mar 10:S0140-6736(22)02535-1. doi: 10.1016/S0140-6736(22)02535.
    PubMed     Abstract available
    
    
    
66. HAWKES S, Kedia S, Odunga S, Dahal M, et al
    From flowers to menstrual-flow trackers: the corporatisation of women's equality and wellbeing.
    Lancet. 2023 Mar 7:S0140-6736(23)00456-7. doi: 10.1016/S0140-6736(23)00456.
    PubMed    
    
    
    February 2023
67. MURRAY CJL
    A systematic analysis points in the wrong direction for cervical cancer elimination - Author's reply.
    Lancet. 2023;401:555-556.
    PubMed    
    
    
    
68. JACKSON A
    A systematic analysis points in the wrong direction for cervical cancer elimination.
    Lancet. 2023;401:555.
    PubMed    
    
    
    
69. DUGOFF L
    The use of cell-free DNA technology in pregnancy loss.
    Lancet. 2023 Feb 1:S0140-6736(23)00182-4. doi: 10.1016/S0140-6736(23)00182.
    PubMed    
    
    
    
70. SCHLAIKJAER HARTWIG T, Ambye L, Gruhn JR, Petersen JF, et al
    Cell-free fetal DNA for genetic evaluation in Copenhagen Pregnancy Loss Study (COPL): a prospective cohort study.
    Lancet. 2023 Feb 1:S0140-6736(22)02610-1. doi: 10.1016/S0140-6736(22)02610.
    PubMed     Abstract available
    
    
    
71. HORNE AW, Tong S, Moakes CA, Middleton LJ, et al
    Combination of gefitinib and methotrexate to treat tubal ectopic pregnancy (GEM3): a multicentre, randomised, double-blind, placebo-controlled trial.
    Lancet. 2023 Feb 1:S0140-6736(22)02478-3. doi: 10.1016/S0140-6736(22)02478.
    PubMed     Abstract available
    
    
    
72. SONALKAR S, Gilmore E
    A fresh look at treatment for ectopic pregnancy.
    Lancet. 2023 Feb 1:S0140-6736(23)00181-2. doi: 10.1016/S0140-6736(23)00181.
    PubMed    
    
    
    January 2023
73. ELLINGTON S, Jatlaoui TC
    COVID-19 vaccination is effective at preventing severe illness and complications during pregnancy.
    Lancet. 2023 Jan 17:S0140-6736(22)02613-7. doi: 10.1016/S0140-6736(22)02613.
    PubMed    
    
    
    
74. VILLAR J, Soto Conti CP, Gunier RB, Ariff S, et al
    Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study.
    Lancet. 2023 Jan 17:S0140-6736(22)02467-9. doi: 10.1016/S0140-6736(22)02467.
    PubMed     Abstract available
    
    
    December 2022
75. SHEIKH J, Allotey J, Kew T, Fernandez-Felix BM, et al
    Effects of race and ethnicity on perinatal outcomes in high-income and upper-middle-income countries: an individual participant data meta-analysis of 2 198 655 pregnancies.
    Lancet. 2022;400:2049-2062.
    PubMed     Abstract available
    
    
    November 2022
76. SAITO M, McGready R, Tinto H, Rouamba T, et al
    Pregnancy outcomes after first-trimester treatment with artemisinin derivatives versus non-artemisinin antimalarials: a systematic review and individual patient data meta-analysis.
    Lancet. 2022 Nov 25:S0140-6736(22)01881-5. doi: 10.1016/S0140-6736(22)01881.
    PubMed     Abstract available
    
    
    
77. SLUTSKER L, Leke RGF
    First-trimester use of ACTs for malaria treatment in pregnancy.
    Lancet. 2022 Nov 25:S0140-6736(22)02166-3. doi: 10.1016/S0140-6736(22)02166.
    PubMed    
    
    
    
78. OLAJIDE N, Robb K, Niedzwiedz C, Jani B, et al
    Cervical cancer risk factors in eight west African countries: cross-sectional analysis of the demographic and health survey 2017-20.
    Lancet. 2022;400 Suppl 1:S68.
    PubMed     Abstract available
    
    
    
79. ANDREAE G, Scott S, Nguyen G, Bell Z, et al
    Food insecurity among pregnant women living in high-income countries: a systematic review.
    Lancet. 2022;400 Suppl 1:S17.
    PubMed     Abstract available
    
    
    October 2022
80. DASHRAATH P, Thong WSE, Ang M, Lee YM, et al
    Interferon shrinks spleen in pregnant patient with myeloproliferative neoplasm.
    Lancet. 2022;400:e11.
    PubMed    
    
    
    
81. BAUD D, Nielsen-Saines K, Mattar C, Musso D, et al
    Monkeypox exposure during pregnancy: what does UK public health guidance advise? - Authors' reply.
    Lancet. 2022;400:1509-1510.
    PubMed    
    
    
    
82. ADLER H, Taggart R
    Monkeypox exposure during pregnancy: what does UK public health guidance advise?
    Lancet. 2022;400:1509.
    PubMed    
    
    
    
83. VAN LENNEP JER, Nerenberg KA
    Delivering evidence to prevent recurrent venous thromboembolism in pregnancy.
    Lancet. 2022 Oct 28. pii: S0140-6736(22)02030.
    PubMed    
    
    
    
84. BISTERVELS IM, Buchmuller A, Wiegers HMG, Ni Ainle F, et al
    Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial.
    Lancet. 2022 Oct 28. pii: S0140-6736(22)02128.
    PubMed     Abstract available
    
    
    
85. HODGETTS MORTON V, Toozs-Hobson P, Moakes CA, Middleton L, et al
    Monofilament suture versus braided suture thread to improve pregnancy outcomes after vaginal cervical cerclage (C-STICH): a pragmatic randomised, controlled, phase 3, superiority trial.
    Lancet. 2022;400:1426-1436.
    PubMed     Abstract available
    
    
    
86. GLYDE T
    LGBTQIA+ menopause: room for improvement.
    Lancet. 2022 Oct 18. pii: S0140-6736(22)01935.
    PubMed    
    
    
    
87. KHALIL A, Samara A, Ladhani S, O'Brien P, et al
    Monkeypox and pregnancy: time for global surveillance and prevention strategies.
    Lancet. 2022;400:1193.
    PubMed    
    
    
    September 2022
88. DONNEZ J, Taylor HS, Stewart EA, Bradley L, et al
    Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials.
    Lancet. 2022;400:896-907.
    PubMed     Abstract available
    
    
    
89. DE LANGE ME, Huirne JAF
    Linzagolix: an oral gonadotropin-releasing hormone receptor antagonist treatment for uterine fibroid-associated heavy menstrual bleeding.
    Lancet. 2022;400:866-867.
    PubMed    
    
    
    August 2022
90. ENDLER M, Petro G, Gemzell Danielsson K, Grossman D, et al
    A telemedicine model for abortion in South Africa: a randomised, controlled, non-inferiority trial.
    Lancet. 2022;400:670-679.
    PubMed     Abstract available
    
    
    
91. WINIKOFF B, Lohr PA
    Randomised trials of medical abortion provide some but not all the answers.
    Lancet. 2022;400:638-639.
    PubMed    
    
    
    
92. ROBERTS SL, Kendall GS, Edwards S, Pandya P, et al
    Screening policies for cytomegalovirus in pregnancy in the era of antivirals.
    Lancet. 2022;400:489-490.
    PubMed    
    
    
    July 2022
93. HAAKENSTAD A, Angelino O, Irvine CMS, Bhutta ZA, et al
    Measuring contraceptive method mix, prevalence, and demand satisfied by age and marital status in 204 countries and territories, 1970-2019: a systematic analysis for the Global Burden of Disease Study 2019.
    Lancet. 2022;400:295-327.
    PubMed     Abstract available
    
    
    
94. PRADHAN MR
    Contraceptive mix and informed choice.
    Lancet. 2022;400:255-257.
    PubMed    
    
    
    
95. JAFFE S
    "Chaos" for patients and providers after US abortion ruling.
    Lancet. 2022;400:85-86.
    PubMed    
    
    
    
96. HIAM L, Mateescu I, Spiegel P
    Improving access to contraception and abortion in Romania in the context of the conflict in Ukraine.
    Lancet. 2022 Jul 8. pii: S0140-6736(22)01275.
    PubMed    
    
    
    
97. JAFFE S
    Federal abortion rights end, but not legal challenges.
    Lancet. 2022;400:13-14.
    PubMed    
    
    
    June 2022
98. DASHRAATH P, Nielsen-Saines K, Mattar C, Musso D, et al
    Guidelines for pregnant individuals with monkeypox virus exposure.
    Lancet. 2022 Jun 21. pii: S0140-6736(22)01063.
    PubMed    
    
    
    
99. GIUDICE LC, As-Sanie S, Arjona Ferreira JC, Becker CM, et al
    Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).
    Lancet. 2022;399:2267-2279.
    PubMed     Abstract available
    
    
    
100. SARASWAT L, Bhattacharya S
     Relugolix combination therapy for endometriosis pain.
     Lancet. 2022;399:2244-2245.
     PubMed    
     
     
     
101. HOLT E
     Poland to introduce controversial pregnancy register.
     Lancet. 2022;399:2256.
     PubMed    
     
     
     
102. THE LANCET
     Attitudes towards menopause: time for change.
     Lancet. 2022;399:2243.
     PubMed    
     
     
     
103. O'BRIEN E, Rich M
     Obstetric violence in historical perspective.
     Lancet. 2022;399:2183-2185.
     PubMed    
     
     
     
104. REED SD, Zhou X, Ichikawa L, Gatz JL, et al
     Intrauterine device-related uterine perforation incidence and risk (APEX-IUD): a large multisite cohort study.
     Lancet. 2022;399:2103-2112.
     PubMed     Abstract available
     
     
     
105. BARTZ D
     Incidence of perforation with intrauterine devices.
     Lancet. 2022;399:2076-2077.
     PubMed    
     
     
     May 2022
106. SCHAEDEL Z, Rymer J
     Menopause care and over the counter vaginal oestradiol.
     Lancet. 2022 May 31. pii: S0140-6736(22)00952.
     PubMed    
     
     
     
107. JARDINE J, Harris T, Khalil A, van der Meulen J, et al
     Adverse pregnancy outcomes: biological essentialism versus embodied biology - Authors' reply.
     Lancet. 2022;399:2014.
     PubMed    
     
     
     
108. RAVI K, Janiak E
     Adverse pregnancy outcomes: biological essentialism versus embodied biology.
     Lancet. 2022;399:2013-2014.
     PubMed    
     
     
     
109. SASIENI P, Castanon A
     HPV vaccination and cervical cancer screening - Authors' reply.
     Lancet. 2022;399:1940.
     PubMed    
     
     
     
110. BEWLEY S
     HPV vaccination and cervical cancer screening.
     Lancet. 2022;399:1939.
     PubMed    
     
     
     
111. KAMAMOTO S, Murayama A, Hamaki T, Kusumi E, et al
     HPV vaccination and cervical cancer screening.
     Lancet. 2022;399:1939-1940.
     PubMed    
     
     
     
112. JAFFE S
     Health organizations fear effects of US abortion ruling.
     Lancet. 2022;399:1854.
     PubMed    
     
     
     
113. VOSS FO, van Beurden M, Jordanova ES
     Topical imiquimod as first-line treatment for vulvar intraepithelial neoplasia.
     Lancet. 2022;399:1755-1757.
     PubMed    
     
     
     
114. TRUTNOVSKY G, Reich O, Joura EA, Holter M, et al
     Topical imiquimod versus surgery for vulvar intraepithelial neoplasia: a multicentre, randomised, phase 3, non-inferiority trial.
     Lancet. 2022;399:1790-1798.
     PubMed     Abstract available
     
     
     
115. DASHRAATH P, Chen K, Htet ZW, Chan SY, et al
     Pre-eclampsia with paradoxical polyuria: diabetes insipidus in pregnancy.
     Lancet. 2022;399:1809.
     PubMed    
     
     
     April 2022
116. MAKONI M
     Hope for access to abortion in Kenya.
     Lancet. 2022;399:1456.
     PubMed    
     
     
     
117. CROSBIE EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, et al
     Endometrial cancer.
     Lancet. 2022;399:1412-1428.
     PubMed     Abstract available
     
     
     March 2022
118. BOOTH A
     Activists welcome Colombia's decriminalisation of abortion.
     Lancet. 2022;399:899.
     PubMed    
     
     
     
119. MANCA T, Baylis F, Munoz FM, Top KA, et al
     Prioritise research on vaccines for pregnant and breastfeeding women.
     Lancet. 2022;399:890-893.
     PubMed    
     
     
     February 2022
120. PASHANKAR R, Prabulos AM, Feder HM Jr
     A woman pregnant with twins has fever, haemolysis, and thrombocytopenia caused by babesiosis: could be confused with HELLP syndrome.
     Lancet. 2022;399:e10.
     PubMed    
     
     
     
121. KALAFAT E, Magee LA, von Dadelszen P, Heath P, et al
     COVID-19 booster doses in pregnancy and global vaccine equity.
     Lancet. 2022 Feb 18. pii: S0140-6736(22)00166.
     PubMed    
     
     
     
122. GERSHENSON DM, Miller A, Brady WE, Paul J, et al
     Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.
     Lancet. 2022;399:541-553.
     PubMed     Abstract available
     
     
     
123. BLAGDEN SP
     Targeting MAPK in recurrent, low-grade serous ovarian cancer.
     Lancet. 2022;399:499-501.
     PubMed    
     
     
     
124. CERDEIRA AS, Ismail L, Moore N, George B, et al
     Retroperitoneal leiomyomatosis: a benign outcome of power morcellation with potentially serious consequences.
     Lancet. 2022;399:554.
     PubMed    
     
     
     January 2022
125. HUG L, You D, Blencowe H, Moran AC, et al
     Strengthening the reporting of stillbirths globally - Authors' reply.
     Lancet. 2022;399:142.
     PubMed    
     
     
     
126. DAS AM, Janardhanan R
     Strengthening the reporting of stillbirths globally.
     Lancet. 2022;399:141.
     PubMed    
     
     
     
127. JOOS O, Swiney C, Sferrazza L
     Strengthening the reporting of stillbirths globally.
     Lancet. 2022;399:140-141.
     PubMed    
     
     
     December 2021
128. JAFFE S
     US Supreme Court expected to weaken abortion rights.
     Lancet. 2021;398:2137-2138.
     PubMed    
     
     
     November 2021
129. SANSON C, Majer M, Pautier P, Gouy S, et al
     Unexplained uterine atrophy following neoadjuvant chemotherapy in fertility sparing management of cervical cancer.
     Lancet. 2021;398:e17.
     PubMed    
     
     
     
130. FALCARO M, Castanon A, Ndlela B, Checchi M, et al
     The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study.
     Lancet. 2021 Nov 3. pii: S0140-6736(21)02178.
     PubMed     Abstract available
     
     
     
131. CRUICKSHANK ME, Grigore M
     Cervical cancers avoided by HPV immunisation.
     Lancet. 2021 Nov 3. pii: S0140-6736(21)02396.
     PubMed    
     
     
     
132. JARDINE J, Walker K, Gurol-Urganci I, Webster K, et al
     Adverse pregnancy outcomes attributable to socioeconomic and ethnic inequalities in England: a national cohort study.
     Lancet. 2021 Nov 1. pii: S0140-6736(21)01595.
     PubMed     Abstract available
     
     
     October 2021
133. THE LANCET
     Abortion bans in the USA harm health equity.
     Lancet. 2021;398:1461.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.